BDF
JAZZ icon

Balasa Dinverno & Foltz’s Jazz Pharmaceuticals JAZZ Stock Holding History

Balasa Dinverno & Foltz’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,377
Closed -$653K – 266
2019
Q4 		$653K Buy
4,377
+1,195
+38% +$163K 0.07% 130
2019
Q3 		$408K Buy
+3,182
New +$427K 0.05% 165

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Balasa Dinverno & Foltz's JAZZ Position: Q1 2020 in Review

Balasa Dinverno & Foltz sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2020, closing a stake of 4,377 shares — an estimated $653K sold.

Balasa Dinverno & Foltz first reported a position in JAZZ in Q3 2019 and held it in 2 quarters. The position peaked at $653K in Q4 2019. 408 funds tracked by Wall St. Rank hold JAZZ as of Q1 2020.

  • Balasa Dinverno & Foltz reported no remaining Jazz Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Balasa Dinverno & Foltz sold 4,377 Jazz Pharmaceuticals shares in Q1 2020, an estimated $653K.
  • Balasa Dinverno & Foltz first reported a position in Jazz Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • Balasa Dinverno & Foltz's Jazz Pharmaceuticals position peaked at $653K in Q4 2019.
  • 408 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2020.

Based on Balasa Dinverno & Foltz's 13F filing for Q1 2020, filed 30 Apr 2020.